Cassava Sciences (SAVA) Alzheimer’s Drug Misrepresentation Case
$SAVA investors filed a lawsuit against Cassava Sciences for misleading them about the effectiveness and risks of their Alzheimer’s drug.
On November 25, 2024, Cassava announced that Simufilam failed to achieve any goals in its Phase 3 trial. Following this news, $SAVA plummeted by 83.76%.
$SAVA investors can join this case to be notified about potential recovery.
Case Details:
Between February 7, 2024, and November 24, 2024, Cassava presented highly optimistic results from simufilam's Phase 2 trials, claiming that mild Alzheimer’s patients showed no cognitive decline after two years of treatment.
In press releases and earnings calls, the company emphasized simufilam’s potential as a "disease-modifying drug" while preparing for its commercial launch.
On November 25, 2024, the company released the topline results for its Phase 3 ReThink-ALZ study, revealing that Simufilam failed to meet any of the pre-specified primary, secondary, and exploratory endpoints.
The announcement also led to the cancellation of other ongoing Phase 3 trials, such as ReFocus-ALZ, and the termination of its open-label extension studies
Following this news, $SAVA dropped by 83.76%.
Based on these events, $SAVA investors filed a lawsuit against Cassava Sciences, accusing the company of the following:
It misled investors about Simufilam’s efficacy and safety.
It downplayed risks associated with the drug’s development and data limitations.
Investors believe Cassava misled them by overstating Simufilam’s effectiveness while downplaying significant risks and limitations.